Pipeline Insight: Antiarrhythmics - RSD1235 in a class of its own

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-05-17

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor believes that RSD1235 (iv) has the potential to have a significant impact on the treatment of atrial fibrillation. In addition, P&G's Stedicor and Sanofi-Aventis' Multaq also offer advances on current treatments, with improvements in efficacy and safety therein.


Scope

  • Evaluation of patient potential for developmental antiarrhythmics over the period 2006-2015
  • Scrutiny of key impacts on the R&D approach and cost, evaluation of optimal clinical trial end points and identification of suitable comparators
  • Evaluation of key players in the arrhthymics market and opposing company approaches to development and commercialization
  • Analysis of key antiarrhymic drugs in development and their ability to satisfy major unmet needs and compete with existing agents


    • Report Highlights
    2005 saw sales in the antiarrhythmics drug market decline. With key problems of current antiarrhythmic drug therapy surrounding their pro-arrhythmic and toxic side effects, it may be sufficient for developmental compounds to demonstrate equivalent efficacy but superior safety profiles to gain market share from the current genericized treatments.

    By 2015 the global antiarrhythmic market will be worth $3.5 billion, with sales of pipeline products accounting for over two thirds of the market by this time. RSD1235 (iv) is predicted to command 27% of the whole market by 2015 on the back of good trial data and the involvement of Astellas in the promotion of the product in the US.

    P&G Pharma's Stedicor (azimilide) looks set to become the most successful orally active antiarrhythmic due to a combination of robust late-stage clinical trial data for Stedicor, particularly from the SHIELD (Shock Inhibition Evaluation with Azimilide) study, and lingering concerns over the relative safety of Sanofi-Aventis' Multaq (dronedarone).


    Reasons to Purchase

  • Explore physician attitudes to the newer antiarrhythmic drugs, and the threats faced by existing and developmental products
  • Predict future market leaders using our independent sales forecasts for products in late stage development in both existing and novel classes
  • Identify early stage antiarrhythmic compounds with high potential being developed by companies seeking a marketing partner

    • Table of Contents

    Other users found this report page using the following search terms: arrhythmia atrial fibrillation ventricular fibrillation pacemaker market antiarrhythmic rsd1235 atrial drugs multaq fibrillation swot tedisamil antiarrythmics

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.